Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- No Complaints Received So Far for Penalty Fee Cuts: MHLW Official
June 10, 2014
- Japan Sees 53-Month Designation Lag, 54-Month Approval Lag for Orphan Drugs
June 9, 2014
- MHLW Designates 20 Products including Allegra FX as Drugs Requiring Face-to-Face Consultations
June 9, 2014
- Researchers Aiming to Craft Guide for Ultra-Orphan Drug Development
June 9, 2014
- JRCS to Use Nucleic Acid Testing on Individual Samples of Donated Blood: PAFSC Committee
June 9, 2014
- MHLW Rejects Proposal to Abolish Market Expansion Re-Pricing Rule
June 6, 2014
- LDP Members with Vested Interests to Oppose Annual Drug Price Revision
June 6, 2014
- MHLW, Pharma Officials Take to Nagata-cho in Crusade against Yearly NHI Price Revision
June 6, 2014
- MHLW Gets Ball Rolling on OTC Diagnostics Deregulation
June 5, 2014
- MHLW Orders Revision of Package Inserts to Urge Caution in Concurrent Use of ARBs and ACE Inhibitors
June 5, 2014
- MOF Budget Examiner Calls for Revising Price-Gap Rule for Key Premium
June 4, 2014
- MHLW Should Clear Hurdles, Revise NHI Prices Annually: MOF Budget Examiner
June 4, 2014
- Gov’t to Discuss Further Reforms of Mixed Care System, Commit to Deregulation: PM Abe
June 4, 2014
- “Difficult” to Include Annual NHI Price Revision in Govt Blueprint: Minister
June 4, 2014
- LDP Members Voice Mixed Opinions on Active Recommendation for HPV Vaccines
June 3, 2014
- TPP Talks over IP Rights Hitting Snag: Cabinet
June 3, 2014
- MHLW Partially Agrees with Gov’t Panel’s Reason for Creation of New Mixed Care Rule
June 2, 2014
- Fiscal System Council Renews Call for Annual NHI Price Revision, MHLW Still Guarded
June 2, 2014
- PAFSC’s First Committee Backs Approval of LEO Pharma’s Ointment for Psoriasis Vulgaris, Shire Japan’s Gaucher’s Disease Drug
June 2, 2014
- MHLW Announces Addition of 9 APIs/11 Products to NHI Price List Including Takeda’s Takelda
June 2, 2014
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…